What is Edwards Lifesciences's market cap?

Edwards Lifesciences (EW) has a market capitalization of $53.9B and trades on NYSE.

What is Edwards Lifesciences's revenue and profitability?

Edwards Lifesciences generated $6.3B in trailing twelve-month revenue with net income of $1.1B, representing a net margin of 17.4%. Gross margin stands at 77.9%, with free cash flow of $1.1B. These figures are based on the Q1 2026 filing.

Who are Edwards Lifesciences's competitors?

Edwards Lifesciences's key competitors include Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, and others. These companies compete in similar markets and product categories.

Where is Edwards Lifesciences headquartered?

Edwards Lifesciences is headquartered in United States of America and employs approximately 19,800 people. It has been publicly traded since 2000.

Edwards Lifesciences

Edwards Lifesciences is a global leader in structural heart innovation, specializing in the development of medical technologies for heart valve disease and critical care monitoring.

Market cap

$53.92B+19.7%

Revenue$6.3B+14.1%

Net income$1.1B-73.8%

Free cash flow$1.1B+57.5%

EPS (diluted)$1.88-73.1%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 23, 2026

Revenue$1.6BBeat by $51.8M EPS$0.78Beat by $0.05

Read the full report

Next report

Jul 23, 2026 (In 1 week)

Revenue estimate$1.7B

EPS estimate$0.73

Financials

Q1 2026

Income statement

See full

Revenue$1.6B+16.7%

Gross profit$1.3B+15.7%

Operating income$477.6M+21.0%

Net income$380.7M+6.3%

EPS (diluted)$0.66+8.2%

Balance sheet

See full

Cash & equivalents$2.4B-22.3%

Total debt$702.9M+0.5%

Total equity$10.3B+2.0%

Total assets$13.3B+2.3%

Cash flow

See full

Operating cash flow$43.8M-84.4%

CapEx$64.9M+15.9%

Free cash flow-$21.1M-109%

Valuation & ratios

Valuation

See full

Market cap$53.92B+19.7%

Enterprise value$52.17B+22.9%

P/E49.2×+38.3×

P/S8.6×+0.6×

Profitability

See full

Gross margin77.9%-1.6pp

Operating margin21.4%-4.4pp

Net margin17.4%-58.3pp

FCF margin17.3%—

Returns & leverage

See full

Return on equity10.7%-37.8pp

Debt / equity0.1×0.0×

Current ratio4.4×0.0×

Segments

By segment

See full

United States$937.6M+11.8%

Europe$442.6M+29.5%

Rest of World$177.8M+18.4%

Japan$90.6M+10.8%

By product

See full

Transcatheter Aortic Valve Replacement$1.2B+14.4%

Surgical$276.2M—

Transcatheter Mitral and Tricuspid Therapies$175.1M+52.0%

Competitors

By market cap

Abbott$165.79B-29.1%

Medtronic$104.98B-7.3%

Boston Scientific$66.6B-56.8%

Edwards Lifesciences$53.9B+19.7%

TFX

Teleflex$5.8B+8.9%

Merit Medical Systems$4.2B-23.4%

ITG

Integer Holdings$3.1B-26.7%

Artivion$1.1B-20.8%

By revenue growth

TFX

Teleflex+25.0%

Artivion+17.6%

Boston Scientific+17.4%

Edwards Lifesciences+14.1%

Merit Medical Systems+11.1%

Medtronic+8.4%

Abbott+6.6%

ITG

Integer Holdings+6.3%

By net margin

Edwards Lifesciences17.39%-58.3pp

Boston Scientific17.26%+5.7pp

Abbott13.91%-18.0pp

Medtronic13.2%-0.7pp

Merit Medical Systems9.03%+0.2pp

ITG

Integer Holdings7.64%+3.2pp

Artivion2.55%+8.0pp

TFX

Teleflex-47.43%-56.2pp

Profile

Edwards Lifesciences is a global leader in structural heart innovation, specializing in the development of medical technologies for heart valve disease and critical care monitoring. The company focuses on transformative product innovation and high-quality clinical evidence to provide both surgical and transcatheter therapies for aortic, mitral, tricuspid, and pulmonic heart valves.

Competitive position

Edwards is the global market leader in transcatheter aortic valve replacement and a pioneer in surgical tissue heart valves.

GeographiesUnited States, Europe, Japan, Rest of World

Customer segmentsHospitals, Specialized Medical Clinics, Healthcare Systems

Business modelMedical Device Manufacturing, Direct Sales, R&D Driven

SuppliersBovine and porcine tissue suppliers, Specialized medical-grade polymers and metals, Electronic component manufacturers for monitoring consoles

CustomersAcute care hospitals, Cardiac catheterization laboratories, Government healthcare providers, Private insurance payers

CountryUnited States of America

Listed2000

Employees19.8K

CEOBernard J. Zovighian

SectorHealthcare

IndustryMedical - Devices

Websiteedwards.com

FilingsSEC EDGAR

Ask your AI about Edwards Lifesciences.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Edwards Lifesciences's market cap?: Edwards Lifesciences (EW) has a market capitalization of $53.9B and trades on NYSE.
What is Edwards Lifesciences's revenue and profitability?: Edwards Lifesciences generated $6.3B in trailing twelve-month revenue with net income of $1.1B, representing a net margin of 17.4%. Gross margin stands at 77.9%, with free cash flow of $1.1B. These figures are based on the Q1 2026 filing.
Who are Edwards Lifesciences's competitors?: Edwards Lifesciences's key competitors include Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, and others. These companies compete in similar markets and product categories.
Where is Edwards Lifesciences headquartered?: Edwards Lifesciences is headquartered in United States of America and employs approximately 19,800 people. It has been publicly traded since 2000.